-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion swings to Q3 2026 net loss of USD 3.54 million year over year

PUBT·11/19/2026 12:05:20
Diffusion vocale
Evaxion swings to Q3 2026 net loss of USD 3.54 million year over year
  • Evaxion swung to a third-quarter 2026 net loss of USD 3.54 million from a year-earlier profit of USD 4.62 million.
  • Revenue fell to nil from USD 7.49 million a year earlier, when results included out-licensing revenue from EVX-B3.
  • Cash totaled USD 13.3 million at September 30, 2026, with cash runway extended toward the end of 2027.
  • The company is refocusing its strategy on immuno-oncology, prioritizing cancer vaccine development and partnerships.
  • An application for a phase 1 trial of off-the-shelf cancer vaccine EVX-04 remains on track for submission before year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190700PRIMZONEFULLFEED1001304474) on November 19, 2026, and is solely responsible for the information contained therein.